Defect size is the starting point for every decision

When a surgeon mentions both OATS and OCA as possibilities, the single most important number is the size of the defect in square centimetres. That measurement, taken from MRI or confirmed at arthroscopy, is the primary reason one technique is chosen over the other.

For lesions larger than roughly 2–4 cm², fresh osteochondral allograft (OCA) transplantation is the standard-of-care choice. Below that threshold — where one or a few plug-sized cores harvested from the patient's own knee can cover the affected area — OATS (Osteochondral Autograft Transfer System) is typically preferred. The 2–4 cm² boundary is not arbitrary: it reflects how much autograft tissue can realistically be taken from the lower-load periphery of the same knee before the harvest site itself becomes a clinical problem.

Real-world practice confirms that OCA cases cluster firmly at the larger end of the spectrum. In a clinical series of 156 knees reported by Tirico et al., the mean allograft area used was 6.4 cm² — well above the upper boundary where autograft alone would suffice. Defects in that series were classified as small (below 5 cm²), medium (5–8 cm²), or large (above 8 cm²), illustrating that surgeons reach for OCA when the lesion has grown beyond what plug transfer can reliably address.

Both techniques are osteochondral procedures, meaning they restore the full depth of tissue — articular cartilage surface and the subchondral bone beneath it. That distinguishes them from surface-only repairs such as microfracture or MACI, which do not address the bony component in the same way. Understanding that shared depth of restoration, and the size threshold that separates them, is the foundation for evaluating everything else about the two approaches.

How OATS works and what the harvest trade-off means

During an OATS procedure, the surgeon harvests one or more cylindrical plugs of bone and cartilage — typically 15–35 mm in diameter — from the lower-load periphery of the same knee, then press-fits them directly into the prepared defect. Everything happens in a single operative session: there is no waiting for donor tissue, no tissue-bank coordination, and no immune-mediated risk because the transferred material is the patient's own.

The practical significance of that is worth emphasising. The plugs carry mature hyaline cartilage — the same tissue type that lines a healthy joint surface — together with the subchondral bone beneath it. Because it is autograft, chondrocyte viability is not in question at the point of implantation in the way it can be with stored allograft tissue.

The hard constraint is harvest capacity. Only a limited volume of osteochondral tissue can safely be removed from the non-load-bearing periphery before the harvest site itself becomes a clinical concern. Donor-site discomfort and the possibility of fibrocartilage fill at the harvest zone — rather than the original hyaline tissue — are genuine considerations that a surgeon will weigh when planning the procedure. They are not minor footnotes; they are the reason OATS cannot simply be scaled up to cover larger defects.

Anatomical access adds a further boundary. Lesions on the very posterior femoral condyle or tibial plateau can be technically difficult to reach and fill cleanly with cylindrical plugs; the geometry of shell allografts used in OCA gives those cases a practical advantage.

How OCA works and why graft viability is time-critical

Fresh osteochondral allograft is not frozen bone-bank tissue. The graft — a shell of donor cartilage and underlying subchondral bone, shaped to match the recipient defect — is stored in a specialised nutrient solution at 4 °C and must be implanted while the chondrocytes within it are still alive. Chondrocyte viability falls measurably after the 14th day post-procurement and typically drops below the accepted threshold of approximately 70% viable cells by day 28. That narrow window is the most clinically distinctive feature of OCA logistics.

Managing it is the responsibility of the tissue bank and surgical team, not the patient. Specialist banks procure, size-match, test, and distribute grafts within this window; scheduling an OCA procedure therefore depends on donor availability and anatomical matching in a way that OATS — harvested and implanted in the same session — does not. Research into improved storage media and thin-plug allograft techniques may extend the viable procurement window and broaden geographic reach in future, but the time-critical constraint remains a practical feature of current OCA pathways.

For the patient, the absence of a harvest site is a genuine advantage. Because the replacement tissue comes from a matched cadaveric donor, there is no donor-site discomfort, no secondary wound, and no risk of fibrocartilage fill at a harvest zone within the same knee.

OCA is also anatomically scalable in ways autograft cannot match. Gross et al. (2008) documented durable long-term viability in posttraumatic knee defects, and the technique has since been studied in the patellofemoral compartment (Chahla et al., Am J Sports Med, 2019) and for femoral condyle lesions via thin-plug approaches — indicating that the range of cases OCA can address continues to expand.

What the evidence shows — and where the gaps are

Both techniques have substantive long-term outcome data — the honest caveat is that almost all of it comes from separate single-arm series, not from trials that pitted OATS directly against OCA in matched patient groups.

For OCA, Gross et al. (2008) established durable long-term viability in posttraumatic knee defects, and Levy et al. (2013) added further follow-up reinforcing OCA as a strategy capable of delaying or avoiding arthroplasty. For OATS, a ten-year study by Gudas et al. (2012) demonstrated durable superiority over microfracture — a meaningful benchmark given that microfracture has historically been the most common comparator for focal defect repair, and one reason OATS has largely displaced it for smaller symptomatic lesions in active patients.

What neither series provides is a head-to-head randomised controlled trial comparing OATS and OCA in equivalent lesion-size cohorts. Pre-clinical mechanistic work — including canine model studies — informs graft biology but cannot substitute for human randomised evidence. This is not unusual in surgical research, where procedure-level randomisation is logistically difficult and patient populations vary considerably. It is worth naming plainly, though: current clinical guidance is a well-reasoned consensus built on lesion-size thresholds, anatomical access, surgeon experience, and individual patient factors, not on a superiority trial favouring either approach.

Both techniques are nonetheless far from experimental in appropriate candidates. The Tirico et al. series of 156 knees, for instance, provides real-world stratification of OCA outcomes by graft area across small, medium, and large lesion categories. The evidence base is genuinely imperfect; it is not thin.

Cost, recovery timeline, and return to sport

Practical planning for either procedure involves three linked questions: what it is likely to cost, how long mobility will be restricted, and when a return to sport is realistic.

In UK private practice, OATS carries an all-inclusive cost of approximately £14,000, compared with approximately £28,000 for OCA. The gap does not reflect greater surgical complexity in OCA; it reflects the procurement chain — donor-tissue acquisition, laboratory processing, size-matching, and the human-tissue regulatory compliance that fresh allograft requires. For patients funding privately whose lesion falls in the small-to-medium overlap zone where either technique is technically feasible, that cost difference becomes a meaningful part of the conversation with a surgeon.

On recovery, OCA protocols typically specify touch-down weight bearing for four to six weeks post-operatively. OATS follows a broadly comparable graduated trajectory, since both procedures depend on subchondral bone integration rather than soft-tissue healing alone. Return to higher-impact sport after OCA is generally delayed to nine to twelve months; OATS timelines are similar in principle, reflecting the same integration requirement.

These figures are anchors, not fixed dates. The supervising clinician will set an individual rehabilitation programme based on imaging findings, clinical progress, and the specifics of the procedure — the calendar is a guide, not a guarantee.

Patient-level factors that shift the decision

Several factors beyond defect size shape which technique fits an individual patient.

Younger, higher-activity patients with a well-defined focal lesion and adequate non-load-bearing periphery at the harvest site are generally well-suited to OATS. OCA becomes the more logical route when the lesion is posttraumatic, geometrically complex, or simply beyond the harvest capacity of autograft plugs — a pattern borne out by the mean graft area of 6.4 cm² seen in the Tirico et al. clinical series.

Donor-site tolerance is worth weighing individually. Patients with prior ipsilateral knee procedures, limited harvestable periphery, or a low threshold for a secondary wound may be better served by OCA regardless of whether defect size alone would exclude autograft.

Geographic access to a tissue bank with an active OCA supply is a practical constraint in some UK regions. Not every centre offering cartilage repair maintains a fresh-allograft pathway; the specialist team will clarify availability during the planning consultation. OATS carries no equivalent logistical dependency — the graft is harvested and implanted in a single session.

Surgeon experience with each technique is a genuine variable. Case volume at the treating unit is a reasonable question to raise at consultation, not because either procedure is experimental, but because osteochondral transfer demands precision that develops with practice.

The size boundary between the two techniques is also not fixed. As thin-plug allograft methods continue to mature, the threshold separating OATS from OCA will likely shift. A specialist consultation will reflect current practice rather than older guidelines — and the Search MSK directory allows patients to filter by region and specialty to identify a clinician with active experience in both approaches.